固本抗纤丸治疗特发性肺间质纤维化的临床效果
|
摘要
目的探讨固本抗纤丸治疗特发性肺间质纤维化的临床效果。方法选取2017年6月至2018年10月于我院肺病科确诊的特发性肺间质纤维化(肺肾气虚兼痰瘀内阻证)患者68例,采用随机数字表法将其分为治疗组与对照组,各34例。对照组给予N-乙酰半胱氨酸泡腾片,治疗组给予固本抗纤丸,两组疗程均为3个月。比较两组治疗总有效率、治疗前、后中医症状评分、6MWT、SpO2、SGRQ评分。结果治疗组治疗总有效率为97.06%,高于对照组的82.35%(P<0.05)。治疗后,治疗组气短、咳嗽、神疲乏力评分均低于对照组(P<0.05)。治疗后,两组患者6MWT、SGRQ评分均优于治疗前,治疗组6MWT、SpO2、SGRQ评分均优于对照组(P<0.05)。结论固本抗纤丸治疗特发性肺间质纤维化(肺肾气虚兼痰瘀内阻证)效果显著,可改善患者临床症状,提高生存质量,值得临床推广应用。
Objective To explore the clinical effect of Guben Kangxian pill in the treatment of idiopathic pulmonary interstitial fibrosis. Methods A total of 68 patients with idiopathic pulmonary interstitial fibrosis(pulmonary kidney Qi deficiency and internal stasis syndrome) diagnosed in our hospital from June 2017 to October 2018 were divided into treatment group and control group by random number table method, with 34 cases in each group. The control group was given N-acetylcysteine effervescent tablets, and the treatment group was given Guben Kangxian pills for 3 months. The total effective rates of treatment, TCM symptoms scores, 6 MWT, SpO2 and SGRQ scores before and after treatment were compared between the two groups. Results The total effective rate of treatment in the treatment group was 97.06%, which was higher than 82.35% of the control group(P<0.05). After treatment, the scores of shortness of breath, cough and fatigue in the treatment group were lower than those in the control group(P<0.05). After treatment, 6 MWT and the scores of SGRQ in the two groups were better than those before treatment, and 6 MWT, SpO2 and the score of SGRQ in the treatment group were better than those in the control group(P<0.05). Conclusion Guben Kangxian pill has a significant curative effect on idiopathic pulmonary interstitial fibrosis(pulmonary kidney Qi deficiency and internal stasis syndrome), which can improve clinical symptoms and the quality of life. It is worthy of clinical promotion and application.
Objective To explore the clinical effect of Guben Kangxian pill in the treatment of idiopathic pulmonary interstitial fibrosis. Methods A total of 68 patients with idiopathic pulmonary interstitial fibrosis(pulmonary kidney Qi deficiency and internal stasis syndrome) diagnosed in our hospital from June 2017 to October 2018 were divided into treatment group and control group by random number table method, with 34 cases in each group. The control group was given N-acetylcysteine effervescent tablets, and the treatment group was given Guben Kangxian pills for 3 months. The total effective rates of treatment, TCM symptoms scores, 6 MWT, SpO2 and SGRQ scores before and after treatment were compared between the two groups. Results The total effective rate of treatment in the treatment group was 97.06%, which was higher than 82.35% of the control group(P<0.05). After treatment, the scores of shortness of breath, cough and fatigue in the treatment group were lower than those in the control group(P<0.05). After treatment, 6 MWT and the scores of SGRQ in the two groups were better than those before treatment, and 6 MWT, SpO2 and the score of SGRQ in the treatment group were better than those in the control group(P<0.05). Conclusion Guben Kangxian pill has a significant curative effect on idiopathic pulmonary interstitial fibrosis(pulmonary kidney Qi deficiency and internal stasis syndrome), which can improve clinical symptoms and the quality of life. It is worthy of clinical promotion and application.
引文
[1]中华医学会呼吸病学分会间质性肺疾病学组.特发性肺纤维化诊断和治疗中国专家共识[J].中华结核和呼吸杂志,2016,39(6):427-432.
[2]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002.
[3]邓斌,王定勇,邓英国,等.沙美特罗替卡松气雾剂对COPD稳定期疗效及Th17表达影响[J].临床误诊误治,2015,28(12):88-91.
[4]刘良徛,张元兵,兰智慧.肺痿诊疗专家共识意见(江西省)[J].江西中医药,2017,48(2):12.
[5]张南星,王至婉.特发性肺间质纤维化的病因病机探析[J].中医研究,2017,30(12):3.
[6]王向阳.抗纤方治疗博来霉素诱导的大鼠肺间质纤维化实验研究[J].中国中医药现代远程教育,2011,9(13):141-142.
[7]陈伊莉,殷贝,李佑生.人工冬虫夏草制剂的作用机制研究[J].河南中医,2018,38(2):313.
[8]徐田田,孔爱华,宁康.特发性肺纤维化的中医治疗新进展[J].临床医学研究与实践,2018,3(16):197-198.
[9]宋文娟,顾伟.龙葵药理学研究进展[J].世界科学技术-中医药现代化,2018,20(2):304.
[10]高攀.金银花临床药理作用的研究进展[J].医学信息,2018,31(23):37.
[2]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002.
[3]邓斌,王定勇,邓英国,等.沙美特罗替卡松气雾剂对COPD稳定期疗效及Th17表达影响[J].临床误诊误治,2015,28(12):88-91.
[4]刘良徛,张元兵,兰智慧.肺痿诊疗专家共识意见(江西省)[J].江西中医药,2017,48(2):12.
[5]张南星,王至婉.特发性肺间质纤维化的病因病机探析[J].中医研究,2017,30(12):3.
[6]王向阳.抗纤方治疗博来霉素诱导的大鼠肺间质纤维化实验研究[J].中国中医药现代远程教育,2011,9(13):141-142.
[7]陈伊莉,殷贝,李佑生.人工冬虫夏草制剂的作用机制研究[J].河南中医,2018,38(2):313.
[8]徐田田,孔爱华,宁康.特发性肺纤维化的中医治疗新进展[J].临床医学研究与实践,2018,3(16):197-198.
[9]宋文娟,顾伟.龙葵药理学研究进展[J].世界科学技术-中医药现代化,2018,20(2):304.
[10]高攀.金银花临床药理作用的研究进展[J].医学信息,2018,31(23):37.